Company intelligence / Profile preview

Algiax Pharmaceuticals

Erkrath, Nordrhein-Westfalen, Germanyalgiax.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Algiax recently completed a Phase 2a clinical trial for AP-325 in chronic neuropathic pain with positive results. The study demonstrated rapid onset of action with clinically meaningful pain reduction within two weeks, persistent treatment effects suggesting disease modification, high responder rates (over 25% of patients showing ≥50% pain reduction vs 11% for placebo), reduced need for rescue medication, favorable Number Needed to Treat compared to standard of care, improved sleep quality, reduced anxiety and depression, and a good safety profile with side effects comparable to placebo and no central side effects.[9][10]

Therapeutic areas: EndocrinologyNeurology
Modalities: Small molecules
Industry: Biotech

Drug pipeline

1 asset

AP-325

Beyond the preview

Go deeper on Algiax Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Algiax Pharmaceuticals.

Explore the full profile